PL2818482T3 - Kompozycja farmaceutyczna do leczenia nowotworu - Google Patents

Kompozycja farmaceutyczna do leczenia nowotworu

Info

Publication number
PL2818482T3
PL2818482T3 PL13751278T PL13751278T PL2818482T3 PL 2818482 T3 PL2818482 T3 PL 2818482T3 PL 13751278 T PL13751278 T PL 13751278T PL 13751278 T PL13751278 T PL 13751278T PL 2818482 T3 PL2818482 T3 PL 2818482T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL13751278T
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2818482T3 publication Critical patent/PL2818482T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13751278T 2012-02-21 2013-02-21 Kompozycja farmaceutyczna do leczenia nowotworu PL2818482T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物
EP13751278.6A EP2818482B1 (en) 2012-02-21 2013-02-21 Pharmaceutical composition for treatment of cancer

Publications (1)

Publication Number Publication Date
PL2818482T3 true PL2818482T3 (pl) 2019-11-29

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13751278T PL2818482T3 (pl) 2012-02-21 2013-02-21 Kompozycja farmaceutyczna do leczenia nowotworu

Country Status (16)

Country Link
US (1) US9273130B2 (pl)
EP (1) EP2818482B1 (pl)
JP (1) JP6187255B2 (pl)
KR (1) KR102009238B1 (pl)
CN (1) CN104169303B (pl)
AU (1) AU2013223143B2 (pl)
CA (1) CA2864864C (pl)
DK (1) DK2818482T3 (pl)
ES (1) ES2739612T3 (pl)
HU (1) HUE044611T2 (pl)
IN (1) IN2014KN01713A (pl)
MX (1) MX360208B (pl)
PL (1) PL2818482T3 (pl)
PT (1) PT2818482T (pl)
RU (1) RU2632645C2 (pl)
WO (1) WO2013125636A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009278386B2 (en) 2008-08-05 2015-05-21 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
RU2603742C2 (ru) * 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MX351414B (es) * 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
CA2864869C (en) 2012-02-21 2021-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX358224B (es) * 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
BR112015001100A2 (pt) 2012-07-19 2018-03-27 Toray Industries, Inc. método de detecção de câncer
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
TWI805127B (zh) 2016-03-04 2023-06-11 美商Jn生物科學有限責任公司 針對tigit之抗體
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP3777888A4 (en) 2018-03-30 2021-12-01 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220034784A (ko) 2019-06-13 2022-03-18 볼트 바이오테라퓨틱스 인코퍼레이티드 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
BR112022006001A2 (pt) 2019-09-30 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
IL292396A (en) 2019-10-25 2022-06-01 Bolt Biotherapeutics Inc Thienoazepine immunoconjugates, and uses thereof
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175129A1 (en) 2020-03-12 2021-09-19 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182574A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
US20230139178A1 (en) * 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119156A4 (en) 2020-03-12 2024-05-08 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
JP2023537940A (ja) 2020-08-13 2023-09-06 ボルト バイオセラピューティクス、インコーポレーテッド ピラゾロアゼピンイムノコンジュゲート、及びその使用
JPWO2022270524A1 (pl) 2021-06-23 2022-12-29
EP4360648A4 (en) 2021-06-23 2025-10-08 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20250325663A1 (en) 2021-07-27 2025-10-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378476A4 (en) 2021-07-27 2025-07-23 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
CN118475372A (zh) 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
CN119486758A (zh) 2022-06-30 2025-02-18 东丽株式会社 癌的治疗和/或预防用药物组合物
EP4578459A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical product for treatment and/or prevention of cancer
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4582101A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582100A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2024135809A1 (ja) 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び/又は予防のための医薬品
EP4665404A1 (en) 2023-02-14 2025-12-24 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
AU762812B2 (en) 1998-07-14 2003-07-03 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092812A1 (fr) 2001-05-11 2002-11-21 Kirin Beer Kabushiki Kaisha CHROMOSOME HUMAIN ARTIFICIEL CONTENANT LE GENE A CHAINE LEGERE DE L'ANTICORPS HUMAIN $g(l)
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
US20050202451A1 (en) 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
RU2402569C2 (ru) 2004-03-19 2010-10-27 Имклоун Элэлси Человеческие антитела к рецептору эпидермального фактора роста
CA2562953A1 (en) 2004-03-30 2005-10-13 Glaxo Group Limited Humanized and chimeric anti-osm antibodies
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
PT3106874T (pt) 2007-10-25 2020-05-08 Toray Industries Método para a deteção de cancro
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
US8663643B2 (en) 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2328426B1 (en) * 2008-07-31 2014-10-01 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
KR20160127146A (ko) 2008-08-05 2016-11-02 도레이 카부시키가이샤 면역 유도제
AU2009278386B2 (en) * 2008-08-05 2015-05-21 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
CA2771441C (en) 2009-08-19 2016-10-11 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
CN102821788B (zh) * 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
US9180187B2 (en) 2010-02-04 2015-11-10 Toray Industries, Inc. Medicament for treating and/or preventing cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
BR112012019098B8 (pt) 2010-02-04 2021-08-17 Toray Industries anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
PL2532366T3 (pl) 2010-02-04 2017-02-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
AU2011284908B2 (en) 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
JP2012035484A (ja) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd 塗膜転写具
MX351682B (es) 2011-08-04 2017-10-25 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
MX351414B (es) 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
MX358224B (es) 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.

Also Published As

Publication number Publication date
HUE044611T2 (hu) 2019-11-28
KR102009238B1 (ko) 2019-08-09
DK2818482T3 (da) 2019-07-15
EP2818482B1 (en) 2019-05-22
MX2014009748A (es) 2014-11-14
JP6187255B2 (ja) 2017-08-30
RU2014138040A (ru) 2016-04-10
RU2632645C2 (ru) 2017-10-06
CA2864864A1 (en) 2013-08-29
CN104169303A (zh) 2014-11-26
JPWO2013125636A1 (ja) 2015-07-30
US9273130B2 (en) 2016-03-01
CA2864864C (en) 2020-05-12
PT2818482T (pt) 2019-08-06
ES2739612T3 (es) 2020-02-03
AU2013223143A1 (en) 2014-09-11
BR112014021101A2 (pt) 2022-03-22
EP2818482A4 (en) 2015-10-07
KR20140130668A (ko) 2014-11-11
WO2013125636A1 (ja) 2013-08-29
US20150004171A1 (en) 2015-01-01
IN2014KN01713A (pl) 2015-10-23
MX360208B (es) 2018-10-24
CN104169303B (zh) 2018-05-29
AU2013223143B2 (en) 2017-12-21
EP2818482A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
HUE044611T2 (hu) Gyógyászati készítmény rák kezelésére
PL2824114T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
PT2818481T (pt) Composição farmacêutica para tratamento e/ou prevenção de cancro
ZA201407726B (en) Pharmaceutical compositions for combination therapy
PL2740796T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740794T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
IL232530A0 (en) Combined cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL228430A0 (en) Cancer treatment
EP2903644A4 (en) TREATMENT OF CANCER
SI2814473T1 (sl) Farmacevtske sestave za kombinirano terapijo
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
GB201217892D0 (en) Treatment of cancer
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
PL2663318T3 (pl) Kompozycja farmaceutyczna do leczenia raka
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
ZA201409502B (en) Composition for treatment of warts
GB201208296D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
PT2814473T (pt) Composições farmacêuticas para terapia de combinação
AU2012905667A0 (en) Vaccines for treatment of cancer